HALIFAX, NOVA SCOTIA--(Marketwired - Sep 3, 2013) - Immunovaccine Inc. ("Immunovaccine" or the "Company") (TSX VENTURE:IMV), a clinical stage vaccine company, today announced that Albert Scardino has been appointed executive chairman and that Marc Mansour, Ph.D. will become chief operating officer of the company.
Mr. Scardino has served as a director of the company since 2010 and as chairman since 2011. Dr. Mansour joined Immunovaccine's scientific team 12 years ago and has served as chief science officer since 2007.
The two appointments at the Halifax, Nova Scotia, vaccine company come after the employment of John Trizzino, chief executive since 2011, came to an end August 31, 2013. Mr. Trizzino will no longer be a director of Immunovaccine. "We wish John all the best in his new endeavors," Scardino said.
Mr. Scardino, 65, has been a director or trustee of numerous private and public companies and charities in the US and UK. Previously, he worked as an editor and reporter for the Associated Press, The New York Times and The Guardian. In 1984 he was awarded the Pulitzer Prize for Editorial Writing at The Georgia Gazette, a newspaper he founded with his wife, Marjorie Scardino, in Savannah, Georgia.
He served in government as press secretary to the Mayor of the City of New York, David Dinkins, and as an adviser to the 1992 presidential campaign of Bill Clinton. Before moving from New York to London in 1993, he was an adviser and speechwriter to the Chairman of the Securities and Exchange Commission, Arthur Levitt.
Dr. Mansour, 40, led the development of Immunovaccine's unique depot-based vaccine adjuvanting platform, bringing it from concept to clinical application. He oversees activities relating to Immunovaccine's cancer vaccines, including DPX-Survivac, a survivin-based vaccine with antigens licensed from Merck KGaA. He also manages product development in infectious diseases with commercial partners and scientific collaborators, including the US National Institutes of Health. Dr. Mansour earned his Ph.D. degree from Dalhousie University.
"Marc has been central to the development of all of our research programs," Scardino said. "In his new role, he will be assuming additional operational responsibilities, including investor relations and marketing."
Immunovaccine develops novel vaccines for cancer and infectious diseases using its patented oil-based delivery system. The company collaborates with government agencies, academic research institutions and major pharmaceutical companies in Canada, the US and Europe to create vaccines for such diseases as ovarian cancer, glioblastoma and anthrax.
The company is working with the National Cancer Institute of Canada to conduct a Phase II study of ovarian cancer. Other programs underway include a Phase I/II study of glioblastoma at the University of Rome, Italy, and a Phase I/II study of breast and ovarian cancer at Busto Arsizio Hospital in Milan, Italy. Immunovaccine expects to launch its first human trial in infectious disease, in respiratory syncytial virus (RSV), in 2014. RSV, a respiratory infection similar to influenza, is a leading cause of death of elderly people.
Immunovaccine Inc. applies its novel adjuvanting platform to the development of vaccines for cancer therapy, infectious diseases and animal health. The Company's DepoVax™ platform is a patented formulation that provides controlled and prolonged exposure of antigens plus adjuvant to the immune system. Immunovaccine has advanced two DepoVax™-based cancer vaccines into Phase I human clinical trials. The Company is also advancing a broad infectious diseases pipeline including vaccines in such indications as malaria, respiratory syncytial virus (RSV) and anthrax. In addition to the Company's human health vaccine strategy, it continues to capture value from animal health vaccine applications. Immunovaccine has key partnerships in the animal health sector including an agreement with Zoetis (formerly Pfizer Animal Health). Connect at www.imvaccine.com.
This press release contains forward-looking information under applicable securities law. All information that addresses activities or developments that we expect to occur in the future is forward-looking information. Forward-looking statements are based on the estimates and opinions of management on the date the statements are made. However, they should not be regarded as a representation that any of the plans will be achieved. Actual results may differ materially from those set forth in this press release due to risks affecting the company, including access to capital, the successful completion of clinical trials and receipt of all regulatory approvals. Immunovaccine Inc. assumes no responsibility to update forward-looking statements in this press release.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.